...
首页> 外文期刊>Scientific reports. >Systems Biology Approach to Identify Novel Genomic Determinants for Pancreatic Cancer Pathogenesis
【24h】

Systems Biology Approach to Identify Novel Genomic Determinants for Pancreatic Cancer Pathogenesis

机译:系统生物学方法识别胰腺癌发病机理的新基因组决定因素。

获取原文
           

摘要

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a 5-year survival rate of 8%. Its dismal prognosis stems from inefficient therapeutic modalities owing to the lack of understanding about pancreatic cancer pathogenesis. Considering the molecular complexity and heterogeneity of PDAC, identification of novel molecular contributors involved in PDAC onset and progression using global "omics" analysis will pave the way to improved strategies for disease prevention and therapeutic targeting. Meta-analysis of multiple miRNA microarray datasets containing healthy controls (HC), chronic pancreatitis (CP) and PDAC cases, identified 13 miRNAs involved in the progression of PDAC. These miRNAs showed dysregulation in both tissue as well as blood samples, along with progressive decrease in expression from HC to CP to PDAC. Gene-miRNA interaction analysis further elucidated 5 miRNAs (29a/b, 27a, 130b and 148a) that are significantly downregulated in conjunction with concomitant upregulation of their target genes throughout PDAC progression. Among these, miRNA-29a/b targeted genes were found to be most significantly altered in comparative profiling of HC, CP and PDAC, indicating its involvement in malignant evolution. Further, pathway analysis suggested direct involvement of miRNA-29a/b in downregulating the key pathways associated with PDAC development and metastasis including focal adhesion signaling and extracellular matrix organization. Our systems biology data analysis, in combination with real-time PCR validation indicates direct functional involvement of miRNA-29a in PDAC progression and is a potential prognostic marker and therapeutic candidate for patients with progressive disease.
机译:胰腺导管腺癌(PDAC)是一种致命的恶性肿瘤,其5年生存率低于8%。由于缺乏对胰腺癌发病机理的了解,其预后不良是由于治疗方式无效。考虑到PDAC的分子复杂性和异质性,使用全局“组学”分析鉴定参与PDAC发病和进展的新型分子贡献者将为改善疾病预防和治疗目标策略铺平道路。对包含健康对照(HC),慢性胰腺炎(CP)和PDAC病例的多个miRNA微阵列数据集进行的荟萃分析,确定了13个参与PDAC进展的miRNA。这些miRNA在组织和血液样本中均显示失调,并且从HC到CP到PDAC的表达逐渐减少。基因-miRNA相互作用分析进一步阐明了5个miRNA(29a / b,27a,130b和148a),它们在整个PDAC进程中伴随着其靶基因的上调而显着下调。在这些基因中,发现在HC,CP和PDAC的比较分析中,miRNA-29a / b靶向基因的变化最大,表明其参与了恶性进化。此外,途径分析表明,miRNA-29a / b直接参与下调与PDAC发育和转移相关的关键途径,包括局部黏附信号传导和细胞外基质组织。我们的系统生物学数据分析与实时PCR验证相结合,表明miRNA-29a在PDAC进展中直接起作用,并且是进行性疾病患者的潜在预后标志物和治疗候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号